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Various automated chemiluminescence immunoassay (CLIA) analyzers for the detection of antibodies to
hepatitis C virus (HCV) are now commercially available in clinical laboratories and are replacing conventional
enzyme immunoassays. We investigated the performance of four anti-HCV CLIAs (the Architect Anti-HCV
assay on the Architect i2000 system, the Vitros Anti-HCV assay on the Vitros ECiQ Immunodiagnostic System,
the Access HCV Ab PLUS assay on the UniCel DxI 800 analyzer, and the newly developed Elecsys Anti-HCV
assay on the Cobas e 411 analyzer). The total percent coefficient of variation values of imprecision were 3.5 to
5.7% with positive control materials and 7.2 to 10.2% with negative control materials. The agreement between
the results of the Elecsys, Architect, Vitros, and Access CLIAs ranged from 94.5 to 98.1%. The clinical
sensitivity of all CLIAs was 100%. Each CLIA showed excellent reproducibility and clinical sensitivity. The
Elecsys, Architect, Vitros, and Access CLIAs showed clinical specificities of 98.2, 98.8, 96.5, and 98.2%.
Hepatitis C virus (HCV), first identified in 1989, is an en-
veloped positive-strand RNA virus classified in the Hepacivirus
genus in the family Flaviviridae (6). The HCV genome is about
9.5 kb in length and encodes 3,011- to 3,033-amino-acid
polypeptides in structural and nonstructural regions (20). The
structural region contains the core protein and two envelope
proteins (E1 and E2), and nonstructural proteins have been
assigned protease (NS2, NS3, and NS4A), helicase (NS3), and
RNA-dependent RNA polymerase (NS5B) (21) functions.
The first commercially available anti-HCV enzyme immu-
noassay (EIA) used a single HCV recombinant antigen derived
from the nonstructural NS4 protein designated c100-3 (19).
The sensitivity of this first-generation EIA was low for a high-
prevalence population (approximately 80%) and showed a
high false-positive rate (up to 70%) in a low-prevalence blood
donor group (13). Therefore, a second-generation EIA was
developed and approved for use by the Food and Drug Ad-
ministration (FDA) in 1992 (3). The second-generation EIA,
which contained additional HCV antigens from the core
(c22-3) and NS3 (c33c) proteins, showed increased sensitivity
and specificity and shortened the average seroconversion pe-
riod from 16 to 10 weeks (1, 3, 13, 18). The third-generation
EIA, which added a fourth antigen (NS5), showed significantly
improved performance, particularly for high-risk patients (2,
8). However, a residual risk still exists due to the seroconver-
sion period of approximately 56 days, and high false-positive
rates were not resolved (12). The Centers for Disease Control
and Prevention (CDC) recommended that an anti-HCV
screening test positive result be verified by a more specific
supplemental assay such as recombinant immunoblot or nu-
cleic acid test (5). To facilitate the use of the supplemental
assay, the revised guideline included an option for reflex sup-
plemental testing based on signal-to-cutoff (s/co) ratios (4).
Today, automated chemiluminescence immunoassay (CLIA)
analyzers are widely used, particularly in high-volume clinical
laboratories. These instruments offer excellent precision and re-
liability, high-speed throughput, random access, and the technical
simplicity of full automation. CLIA showed significantly improved
specificity, a greater positive predictive value, and a similar sen-
sitivity compared to those of EIA for detecting anti-HCV anti-
bodies (10, 15). Although automated CLIAs are gradually replac-
ing the EIA, there are no published studies on the comparative
evaluation of automated CLIAs (10, 15, 16, 22, 27). We compared
the performance of currently marketed anti-HCV automated
CLIAs under routine conditions of a hospital laboratory.
MATERIALS AND METHODS
Assay systems. Four automated CLIAs were compared, the Elecsys Anti-HCV
assay on the Cobas e 411 analyzer (Roche Diagnostics, Mannheim, Germany), the
Architect Anti-HCV assay on the Architect i2000 system (Abbott Laboratories,
Abbott Park, IL), the Vitros Anti-HCV assay on the Vitros ECiQ Immunodiagnostic
System (Ortho-Clinical Diagnostics, Raritan, NJ), and the Access HCV Ab PLUS
assay (Bio-Rad Laboratories, Redmond, WA) on the UniCel DxI 800 analyzer
(Beckman-Coulter, Fullerton, CA). The characteristics of the four reagents and the
technical specifications of each instrument are summarized in Table 1.
Precision tests of four CLIAs. The reproducibility of each CLIA was deter-
mined by using a modified form of the EP5-A2 protocol of the Clinical and
Laboratory Standards Institute (7). Experiments were performed twice a day for
10 days in duplicate with negative and positive quality control materials recom-
mended by each manufacturer.
CLIA screening. A total of 400 consecutive unselected fresh serum samples
sent daily to our laboratory underwent anti-HCV testing with four CLIAs. We
prospectively collected HCV-positive samples screened by Genedia HCV ELISA
3.0 (Greencross Life Science, Seoul, Korea) from December 2007 to April 2008.
These sera, which had been stored frozen at 20°C, were then tested with the
four CLIAs and for HCV RNA. However, there were limitations in sample
volume; the Vitros and Access assays were performed with only 127 and 140
samples, respectively. The four anti-HCV CLIAs were carried out according to
the manufacturers’ instructions.
Confirmation of results. Samples showing positive results from any CLIA were
investigated by medical record review and confirmatory testing. The medical
record review involved the examination of any clinical or laboratory evidence of
chronic HCV infection. These samples were investigated for the presence of
* Corresponding author. Mailing address: Department of Labora-
tory Medicine, Yonsei University College of Medicine, 134-Sinchon-
dong, Seodaemun-gu, CPO Box 8044, Seoul, Korea. Phone: (82)
2-2228-2443. Fax: (82) 2-313-0956. E-mail: kimhs54@yuhs.ac.
 Published ahead of print on 22 October 2008.
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clinical conditions that could interfere with the accuracy of CLIA results such as
autoimmune disease, dialysis, pregnancy, bacterial infection, and rheumatoid
factor.
Measurements of HCV RNA were performed with samples with undeter-
mined HCV status by medical record review and any discrepancy in the CLIA
results. HCV RNA was detected by the COBAS Amplicor HCV 2.0 qualitative
assay and the COBAS TaqMan HCV assay (both from Roche Diagnostics). In
the COBAS Amplicor HCV 2.0 assay, the viral genome was extracted with the
HCV Specimen Preparation Kit; details of the assay have been described else-
where (25). The lower detection limit of the COBAS Amplicor HCV 2.0 assay is
50 IU/ml. In the COBAS TaqMan HCV assay, the viral genome was extracted by
automated COBAS AmpliPrep instruments and HCV RNA was amplified and
detected with the COBAS TaqMan Analyzer (24). The lower detection limit of
the COBAS TaqMan HCV assay is 15 IU/ml.
Recombinant immunoblot assays (RIBA) were additionally performed with
samples with HCV RNA-negative results by using LG HCD Confirm (LG Life
Sciences, Seoul, Korea) according to the manufacturer’s instruction.
RESULTS
Precision. The precision of each CLIA was evaluated by using
the commercial negative and positive control materials recom-
mended by each manufacturer. Each control was run twice a day
for 10 days in duplicate (40 runs in 10 days). Precision results for
each CLIA are shown in Table 2. Intra-assay and total percent
coefficient of variation values for positive controls ranged from 2.8
to 4.7% and 3.5 to 5.7%, respectively. Due to low mean values for
the negative control, intra-assay and total percent coefficient of
variation values for negative controls ranged from 5.5 to 9.1% and
7.2% to 10.2%, respectively.
Comparison of CLIA results. The overall correlation of the
results of the four CLIAs is shown in Table 3. The agreement
between the results of the Elecsys, Architect, and Vitros
CLIAs ranged from 97.1 to 98.1%. The agreement between the
results of the Access CLIA and the other CLIAs ranged from
94.5 to 97.0%.
There was a limitation on sample volume; the Access CLIA
could not be performed with every sample, and the percent
agreement ranged from 94.5 to 97.0%, slightly lower than that
of the others. Among 267 samples assayed by all of the CLIAs
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TABLE 2. Intra-assay and total assay precision results of
each CLIA
Reagent
and
sample
Grand mean
(s/co)
SDa (%CV)b
Intra-assay Total
Elecsys
NCc 0.134 0.011 (7.8) 0.014 (10.2)
PCd 9.58 0.451 (4.7) 0.543 (5.7)
Architect
NC 0.074 0.007 (9.1) 0.006 (8.3)
PC 3.21 0.115 (3.6) 0.129 (4.0)
Vitros
NC 0.232 0.015 (6.5) 0.023 (9.9)
PC 5.53 0.173 (3.1) 0.191 (3.5)
Access
NC 0.097 0.005 (5.5) 0.007 (7.2)
PC 3.06 0.084 (2.8) 0.138 (4.5)
a SD, standard deviation of s/co ratio.
b CV, coefficient of variation of s/co ratio.
c NC, negative control material.
d PC, positive control material.
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(Table 4), the overall concordance rate was 94.0% (251/267).
Sixteen samples showing discrepant results were confirmed
negative by either the COBAS Amplicor HCV 2.0 qualitative
assay or the COBAS TaqMan HCV assay for detection of
HCV RNA. Furthermore, an additional confirmatory RIBA
was performed with 14 of 16 HCV RNA-negative samples; the
remaining 2 samples could not be confirmed by RIBA due to
lack of sample volume. Ten samples were RIBA negative, and
four were RIBA indeterminate.
Clinical specificity. To assess the specificity of each CLIA,
we confirmed HCV infectious status with the following algo-
rithm. Among 267 samples assayed by all CLIAs, 160 showing
negative results in all CLIAs were categorized as “screening
test negative” and did not undergo any supplemental testing as
recommended by the CDC (4). Among 107 samples showing
positive results in any of the CLIAs, 54 were further investi-
gated based on clinical data and medical record review as
described above due to insufficient sample volume as a result
of the consumption of large volumes during comparison ex-
periments and repeat tests. Therefore, 30 samples were further
categorized as “clinically confirmed positive” and 24 in which
HCV status could not be confirmed were excluded from the
specificity analysis.
The other 53 samples were tested for HCV RNA. If HCV
RNA test were negative, a further confirmatory RIBA was
performed. Any samples showing indeterminate HCV RNA or
RIBA results were excluded from the specificity analysis. The
specificity of each CLIA ranged from 96.5 to 98.8% (Table 5).
There were no false-negative results from any CLIA, making
the sensitivity of each assay 100% in our experiment.
Detection of HCV RNA in relation to CLIA s/co ratios. We
analyzed the s/co ratio result of samples confirmed by HCV
RNA and RIBA or confirmed by retrospective medical record
review (clinically confirmed positive). The number of cases
with HCV infection increased in relation to the s/co ratio
(Table 6). In the Vitros assay, only 1 (5.9%) of 17 cases with an
s/co ratio of 8.0 had HCV infection. In the Architect and
Access assays, 1 (7.1%) of 14 and 1 (5.9%) of 17 cases with an
s/co ratio of 3.0 had HCV infection, respectively. However,
in the Elecsys, we could not precisely identify the s/co ratio
predictive of HCV infection negativity for more than 95% of
the samples due to the paucity of samples with a low s/co ratio.
The guidelines for laboratory testing and result reporting of
antibodies to HCV from the CDC (4) include an option for
reflex supplemental testing based on screening test-positive
s/co ratios. Use of s/co ratios could minimize the amount of
supplemental testing that needs to be performed while improv-
ing the reliability of reported test results. In short, screening
test-positive results are classified as having high s/co ratios if
their ratios are at or above a predetermined value that predicts
a supplemental test (HCV RNA or RIBA) positive result for
95% of the samples tested. However, only the Vitros Anti-
HCV assay has been approved by the FDA and an s/co ratio of
8.0 was set as the screening test positive value to determine the
need for reflex supplemental tests. With our data, we set the
cutoff s/co ratios as follows: Elecsys assay, 200 (89 [95.7%] of
93); Architect assay, 3 (93 [94.9%] of 98); Vitros assay, 7.0
(67 [95.7%] of 70); Access assay, 3 (90 [94.7%] of 95).
DISCUSSION
Since anti-HCV EIAs using recombinant antigen were in-
troduced in 1990, they have been widely used for clinical di-
TABLE 3. Results of comparison of each anti-HCV CLIA for a
clinical specimen
Reagent and
result
No. of samples negative, no. positive or % agreement between
two CLIAs (no. of identical results/total)
Elecsys
(n  585)
Architect
(n  585)
Vitros
(n  527)
Access
(n  325)
Elecsys
Negative 425, 10 413, 11 168, 14
Positive 7, 143 3, 100 4, 139
Architect 97.1 (568/585)
Negative 414, 8 167, 13
Positive 2, 103 5, 140
Vitros 97.3 (513/527) 98.1 (517/527)
Negative 165, 1
Positive 7, 94
Access 94.5 (307/325) 94.5 (307/325) 97.0 (259/267)
Negative
Positive
TABLE 4. Comparison of 267 samples assayed by four CLIA methods
No. (%) of
samplesc
CLIA result
RIBA result(s) (n)
Elecsys Architect Vitros Access
160 (59.9) Negative Negative Negative Negative NTa (160)
91 (34.1) Positive Positive Positive Positive NT (91)
4 (1.5) Negative Negative Positive Negative Negative (3), INDb (1)
3 (1.1) Positive Negative Negative Negative Negative (2), NT (1)
2 (0.7) Negative Positive Negative Negative Negative (1), NT (1)
2 (0.7) Negative Positive Positive Negative Negative (1), IND (1)
1 (0.4) Negative Negative Negative Positive Negative (1)
1 (0.4) Negative Negative Positive Positive Negative (1)
1 (0.4) Negative Positive Positive Positive IND (1)
1 (0.4) Positive Negative Positive Positive Negative (1)
1 (0.4) Positive Positive Positive Negative IND (1)
a NT, not tested.
b IND, indeterminate result.
c The total number of samples was 267, and the overall concordance rate was 94.0%.
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agnosis and screening of asymptomatic persons. With the de-
velopment of newer generations of EIAs, sensitivity and
specificity were greatly improved (8). For HCV screening of a
population of blood donors, the most sensitive test should be
chosen to avoid false-negative results. On the contrary, for
screening of patients to be treated, false-positive results should
be avoided. The CDC has recommended performing reflex
supplemental testing for low s/co ratios of screening test pos-
itive results to resolve false-positive results (4).
Recently, various assay formats of anti-HCV CLIAs have
been developed, and they offer the great advantages of im-
proved precision, reliability, technical simplicity, short turn-
around time, high-speed throughput, and full automation, par-
ticularly for high-volume hospital laboratories. Furthermore,
CLIAs have improved specificity and a greater positive predic-
tive value than conventional EIAs and result in fewer low-
positive samples that require confirmatory testing (10). In the
present study, we assessed the clinical performance of four
automated CLIAs available in our laboratory to help in select-
ing the anti-HCV CLIA format and instruments. Among the
four systems, only the Vitros assay contains the NS5 antigen of
HCV and the Elecsys uses a ruthenium complex as a labeled
substance for EIA.
The percent agreement among the results of the four CLIAs
ranged from 94.5 to 98.1%. The Access assay showed a lower
concordance rate than the others because of the smaller num-
ber of negative samples tested. Previous reports on the perfor-
mance evaluation of anti-HCV CLIAs usually compared the
results of a CLIA with those of an EIA. Therefore, there are
no available data to compare to our results. In addition, the
Elecsys Anti-HCV and Access HCV Ab PLUS assays have
never been studied. The best correlation (98.1%) was found
between the results of the Architect and Vitros assays. The
HCr43 and c100-3 HCV antigens in the Architect assay are
known to be prepared under contract agreement by Ortho
Diagnostic Systems and the Chiron Corporation. This may
explain why the best correlation was found between the results
of the Architect and Vitros assays.
Among 257 samples tested by the four CLIAs, discrepant
results were obtained with 16. These 16 samples were con-
firmed negative for HCV RNA. The number of false-positive
results based on HCV RNA results were 5 (1.9%), 6 (2.2%), 10
(3.7%), and 4 (1.5%) by the Elecsys, Architect, Vitros, and
Access assays, respectively. The United Kingdom Health Pro-
tection Agency has recommended the use of a second anti-
HCV antibody EIA for the confirmation of positive samples in
the National Standard Method Minimum Testing Algorithm
for the investigation of HCV infection (14). This algorithm is
more cost effective and could reduce the number of samples in
the problematic immunoblot-indeterminate group when fol-
lowing the CDC guidelines (17, 26). Among the discordant
samples, the number of cases in which only one of the four
CLIAs gave a positive result was 10 (63%). If we choose two
CLIA formats for screening and confirmation, false-positive
reactions are dramatically decreased, theoretically, for certain
combinations of CLIAs.
TABLE 5. Specificity of each CLIA on samples confirmed by additional confirmatory test or retrospective medical record review
Test result(s) (no. of samples)
No. of samples tested by:
Elecsys Architect Vitros Access
Positive Negative Positive Negative Positive Negative Positive Negative
Screening test negative (160) 0 160 0 160 0 160 0 160
Clinically confirmed positive (30) 30 0 30 0 30 0 30 0
HCV RNA positive (35) 35 0 35 0 35 0 35 0
HCV RNA indeterminate (2)a 2 0 2 0 2 0 2 0
HCV RNA negative, RIBA negative (10) 3 7 2 8 6 4 3 7
HCV RNA negative, RIBA indeterminate (4)a 1 3 3 1 4 0 1 3
a Indeterminate results of the HCV RNA test and RIBA were excluded from the analysis. Clinical specificity: Elecsys, 98.2%; Architect, 98.8%; Vitros, 96.5%; Access,
98.2%.
TABLE 6. HCV infection status in relation to CLIA s/co ratio
CLIA and
s/co ratio
No. of cases in
each group
No. (%) of cases with
HCV infection
Elecsys
1–200 13 5 (38.5)
200–400 24 21 (87.5)
400–1,000 56 55 (98.2)
1,000 13 13 (100)
Total 106 94 (88.7)
Architect
1.0–3.0 14 1 (7.1)
3.0–10.0 12 7 (58.3)
10.0–15.0 68 68 (100)
15.0 18 18 (100)
Total 112 94 (83.9)
Vitros
1.0–8.0 17 1 (5.9)
8.0–20.0 6 4 (66.7)
20.0–30.0 56 56 (100)
30.0 7 7 (100)
Total 86 68 (79.1)
Access
1.0–3.0 17 1 (5.9)
3.0–10.0 13 9 (69.2)
10.0–15.0 75 74 (98.7)
15.0 7 7 (100)
Total 112 91 (81.3)
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We investigated the clinical specificity of four CLIAs. The
clinical specificity was 98.8% in the Architect assay, 98.2% in
the Elecsys and Access assays, and 96.5% in the Vitros assay.
The major difference among the four CLIAs is the inclusion of
NS5 in the Vitros Anti-HCV assay. However, it is not clear that
the addition of recombinant HCV NS5 protein in the assay
format may be responsible for nonspecific reactivity (11, 27).
Based on our data, the absence of NS5 protein in the assay
format seems to improve the specificity of the anti-HCV CLIA.
The 2003 CDC guidelines for laboratory testing and result
reporting of antibody to hepatitis C virus (4) require the use of
a screening assay with high sensitivity and, for samples with low
s/co ratios, confirmation by a recombinant immunoblot or PCR
test. Among the available anti-HCV CLIAs on the market,
only the Vitros assay has been approved by the FDA, and an
s/co ratio of 8.0 was set as the screening test positive value to
determining the need for reflex supplemental tests. Oethinger
et al. (23) reported that 99% of the samples with very low
s/co ratios tested by the Ortho Vitros anti-HCV assay had no
evidence of HCV infection. Furthermore, they decided to re-
port the results of samples with low s/co ratios between 1 and
5 as “borderline,” with the recommendation that follow-up
testing be performed when HCV infection continues to be
suspected. We investigated s/co ratios of four CLIAs according
to HCV infection status. As mentioned above, HCV infection
status was determined by HCV RNA and evaluation of clinical
data. For the Vitros assay, we could set a cutoff s/co ratio of 7.0
to predict a supplemental test positive result for more than
95% of the samples, similar to that of 8.0 assigned by the CDC
(4). Similarly, a cutoff s/co ratio of 3.0 could be used for the
Architect and Access assays and a cutoff s/co ratio of 200 could
be used for the Elecsys assay.
According to the European Union standards (9), anti-HCV
assays were required to have a sensitivity and a specificity of
100% and 99.5% for market approval, respectively. In our
study, four anti-HCV CLIAs showed an excellent sensitivity of
100% and a good concordance rate. The clinical specificity
varied from 96.5 to 98.8%, and the Elecsys, Architect, and
Access assays showed specificities of 98%.
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